Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-96

India would not have reordered without success in vivo.

It's likely they've successfully produced embryos using our tech and implanted them.

We don't need to wait for healthy births to know they process is a success - healthy embryos and successful pregnancies is enough.

If we can get their data and use it to prove the tech works, we may be able to enter early access markets without the large trial.

We don't need to prove superiority (thought that would be nice, and in theory we should show that), we just need non-inferiority, as it's superior in other ways (faster, less man power).

The trial will be necessary for most markets. But I hope we can get sales before it completes, or we will be waiting until next CY at the earliest (and another cap raise).

The reorder makes me think the tech works. The issues with KOLs not ordering make me question whether management works.

It's a long term hold. Unfortunately, for us LTHers, the can keeps getting kicked down the road not due to poor tech, but because of poor planning.